Peptide Therapeutics: An Analysis on the Clinical Trials
by Roots Analysis Roots Analysis provides market research and consulThe number and geographical distribution of
clinical trials are important indicators of both the therapeutic viability and
future potential of innovative pharmacological interventions. These trials
enable CDMOs / CMOs to estimate the clinical demand of peptide
therapeutics across different geographies, therapeutic areas and trial
phase. Moreover, the geographical distribution is a direct indicator of the
various markets that are conducting trials or enrolling patients for clinical
studies. Further, as more product candidates are approved by regulatory
authorities across the globe, the number of clinical trials are also anticipated
to increase.
Majority of the completed / ongoing /
planned trials for peptide therapeutics are centered in North America. Further,
within this region, the US (623) emerged as the most prominent hub for
conducting clinical trials for peptide therapeutics. Within Europe, the maximum
number of trials (125) were reported to be / have been conducted in Germany. In
Asia Pacific, the maximum number of peptide therapeutics focused trials were
registered in Georgia (114), followed by India (96).
Majority (330) of the active clinical
trials are being conducted in North America, wherein more than 40% of the
trials are currently in phase II. Similarly, in Europe, majority (46%) of the
active trials are in phase II. Whereas, in Asia Pacific and rest of the world,
most of the active clinical trials are in phase III. This indicates that there is a higher
clinical demand in North America and Europe, as compared to Asia Pacific, where
a significant number of active trials are inching towards completion.
The maximum number of patients were
enrolled in studies being conducted in North America. Within this region, most
of the patients were enrolled in the US (70,384). In Europe, most of the
patients were enrolled for peptide therapeutics-based studies in the UK (8,665).
Within Asia Pacific, majority of the patients were enrolled in studies based in
China (15,883). The majority (70%) of the patients were enrolled in phase III
clinical trials in North America.
Majority (63%) of the active trials are
evaluating peptide
therapeutics intended for the treatment of oncological disorders, primarily
multiple myeloma and prostate cancer. This is followed by studies evaluating
peptides targeting metabolic disorders (14%) and cardiovascular disorders (4%).
Other prominent therapeutic areas include genetic disorders, neurological
disorders and gastroenterological disorders.
Similarly, majority (60%) of the patients were enrolled for trials
evaluating peptide therapeutics intended for the treatment of oncological
disorders, primarily for multiple myeloma and prostate cancer. This is followed
by patients enrolled in trials for peptides targeting metabolic disorders (22%)
and cardiovascular disorders (4%).
Sponsor Ads
Created on Aug 20th 2020 06:26. Viewed 247 times.